Nm23/nucleoside diphosphate kinase-A as a potent prognostic marker in invasive pancreatic ductal carcinoma identified by proteomic analysis of laser micro-dissected formalin-fixed paraffin-embedded tissue by Tatsuyuki Takadate et al.
CLINICAL
PROTEOMICS
Takadate et al. Clinical Proteomics 2012, 9:8
http://www.clinicalproteomicsjournal.com/content/9/1/8RESEARCH Open AccessNm23/nucleoside diphosphate kinase-A as a
potent prognostic marker in invasive pancreatic
ductal carcinoma identified by proteomic analysis
of laser micro-dissected formalin-fixed
paraffin-embedded tissue
Tatsuyuki Takadate1, Tohru Onogawa1*, Kiyonaga Fujii2, Fuyuhiko Motoi1, Sayaka Mikami3, Tetsuya Fukuda3,
Makoto Kihara4, Takashi Suzuki5, Taro Takemura6, Takashi Minowa6, Nobutaka Hanagata6, Kengo Kinoshita7,
Takanori Morikawa1, Keiichi Shirasaki1, Toshiki Rikiyama1, Yu Katayose1,8, Shinichi Egawa1, Toshihide Nishimura9
and Michiaki Unno1,8Abstract
Background: Pancreatic cancer is among the most lethal malignancies worldwide. This study aimed to identify a
novel prognostic biomarker, facilitating treatment selection, using mass spectrometry (MS)-based proteomic analysis
with formalin-fixed paraffin-embedded (FFPE) tissue.
Results: The two groups with poor prognosis (n = 4) and with better prognosis (n = 4) had been carefully chosen
among 96 resected cases of pancreatic cancer during 1998 to 2007 in Tohoku University Hospital. Although those 2
groups had adjusted background (UICC-Stage IIB, Grade2, R0, gemcitabine adjuvant), there was a significant
difference in postoperative mean survival time (poor 21.0 months, better 58.1 months, P = 0.0067). Cancerous
epithelial cells collected from FFPE tissue sections by laser micro-dissection (LMD) were processed for liquid
chromatography-tandem mass spectrometry (LC-MS/MS). In total, 1099 unique proteins were identified and 6
proteins showed different expressions in the 2 groups by semi-quantitative comparison. Among these 6 proteins,
we focused on Nm23/Nucleoside Diphosphate Kinase A (NDPK-A) and immunohistochemically confirmed its
expression in the cohort of 96 cases. Kaplan-Meier analysis showed high Nm23/NDPK-A expression to correlate with
significantly worse overall survival (P = 0.0103). Moreover, in the multivariate Cox regression model, Nm23/NDPK-A
over-expression remained an independent predictor of poor survival with a hazard ratio of 1.97 (95% CI 1.16-3.56,
P = 0.0110).
Conclusions: We identified 6 candidate prognostic markers for postoperative pancreatic cancer using FFPE tissues
and immunohistochemically demonstrated high Nm23/NDPK-A expression to be a useful prognostic marker for
pancreatic cancer.
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Pancreatic cancer has the worst prognosis of any major
malignancy, with a 5-year survival rate of less than 5% after
diagnosis [1]. It is the fifth leading cause of cancer death
and the incidence of pancreatic cancer is rising in Japan
[2,3]. The majority of exocrine pancreatic cancers are inva-
sive ductal carcinomas. Radical surgical resection is the
only chance for cure, but only 10% to 20% of patients are
candidates for curative resection, [2] and even if curative
resection is performed, the postoperative 5-year survival
rate is only 15% to 25% because of high recurrence rates
[4,5]. In an effort to explain improved survival rates, several
studies have analyzed determinants of long-term survival
in postoperative pancreatic cancer patients [6-15]. How-
ever, the prognosis of pancreatic cancer patients has
improved little in the past 20 years [2]. Thus, there is an
urgent need to identify novel molecular targets for early
diagnosis and selecting optimal treatments.
In recent decades, many exploratory studies have aimed
to discover biomarkers for early detection, optimal treat-
ment selection and predicting therapeutic outcomes, with
the goal of improving prognosis [16]. Proteomics has be-
come a major tool for the discovery of diagnostic and
prognostic cancer biomarkers, but pancreatic cancer ana-
lysis is challenging due to histological heterogeneity within
the tumor. However, laser micro-dissection (LMD)
provides an ideal method of extracting tumor specimens
and isolating targeted cells with defined morphologies.
Formalin-fixed paraffin-embedded (FFPE) tissues, long
collected and stored in hospitals worldwide, represent an
enormous untapped information resource concerning dis-
ease progression as well as drug responses and toxicity.
FFPE tissue is particularly advantageous for discovering
biomarkers because of the wealth of accompanying clin-
ical data [17,18].
We performed retrospective proteomics by liquid chro-
matography–tandem mass spectrometry (LC-MS/MS)
using FFPE tissues from resected invasive pancreatic ductal
carcinomas and semi-quantitative group comparison. To
identify novel prognostic biomarkers, we selected 2 groups
with poor prognosis and better prognosis. We focused on
differentially expressed proteins between the 2 groups and
immunohistochemically confirmed the candidate proteins
in a cohort of 96 cases of invasive pancreatic ductal
carcinoma.
Methods
Patient characteristics and FFPE tissue samples
The study subjects were selected from among 156
histologically diagnosed invasive pancreatic ductal carcin-
oma cases undergoing pancreatectomy during the January
1998 through December 2007 period at our hospital. We
selected 96 cases suitable for monitoring, with micro-
scopic complete resection (R0), and no neoadjuvantchemotherapy (Figure 1). To identify novel biomarkers,
we standardized known prognostic factors: 1) patho-
logical stage, [6-8,10-12,14] 2) histological differentiation,
[10,12,14] 3) postoperative carbohydrate antigen 19–9
(CA19-9) level, [19] and 4) adjuvant chemotherapy
[9,10,13,15]. We excluded 3 cases because the observation
period was too short, leaving 8 cases divided into 2 groups,
poor prognosis (n = 4) and better prognosis (n = 4), for
shotgun proteomic analysis (Figure 1). There was a signifi-
cant difference in postoperative mean survival time (poor
21.0 ± 4.8 months, better 58.1 ± 13.0 months, P = 0.0067).
First, we performed shotgun proteomic analysis using
FFPE tissues from these 8 invasive pancreatic ductal car-
cinomas. FFPE tissues were utilized for this semi-
quantitative proteomic study with approval from the Ethics
Committee of Tohoku University (2006–119), and
informed consent was obtained from individual patients.
LMD and protein extraction
Tumor tissues were fixed in 4% paraformaldehyde and
routinely processed for paraffin sectioning. Cancerous
lesions were identified on serial sections stained with
hematoxylin and eosin. For shotgun proteomic analysis,
10-μm sections prepared from the same tissue block
were attached to DIRECTOR™ slides (Expression Path-
ology, MD, USA), de-paraffinized three times with xy-
lene for 5 min, rehydrated with graded ethanol
solutions and distilled water, and then stained with
hematoxylin. Stained, uncovered slides were air-dried
and approximately 30,000 cancerous cells (8 mm2)
were collected into the cap of a 0.2 mL PCR tube
using Leica LMD6000 (Leica Microsystems GmbH,
Germany). Peptides were extracted using a Liquid
Tissue™ MS Protein Prep kit (Expression Pathology)
[20] according to the manufacturer’s instructions.
Briefly, the cellular material, suspended in the Liquid
Tissue buffer, was incubated at 95C for 90 min, then
cooled on ice for 3 min. Trypsin was added (approxi-
mately 15–18 U) followed by incubation at 37C
overnight. Dithiothreitol was added to a final concen-
tration of 10 mM, and the samples were heated for
5 min at 95C. The Liquid Tissue digestate was
stored at −20C until analysis.
LC-MS/MS shotgun analysis
Exploratory LC-MS/MS analysis of a digested sample
was performed using reversed phase (RP)-LC interfaced
with an LTQ-Orbitrap hybrid mass spectrometer (Thermo
Fisher Scientific, Germany) using a nanoelectrospray
device (AMR, Tokyo, Japan), as previously reported [21].
The RP-LC system (Paradigm MS4B, Michrom
BioResources, CA, USA) consisted of a peptide Cap-Trap
cartridge (2.0 × 0.5 mm inside diameter) and an analytical
column (L-column Micro, 150 × 0.2 mm L-C18, 3 μm,
Figure 1 Patient selection for proteomic analysis. a Histological residuum R0 shows microscopically negative margins. b Unio Internationalis
Contra Cancrum/Union for International Cancer Control. UICC stage IIB: Cancer has spread to nearby lymph nodes and may also have spread to
adjacent tissues and organs. c Japan Pancreas Society. JPS stage 3: Cancer has not extended into the portal vein, extra-pancreatic nerve plexus, or
other organs in UICC stage IIB. d Formalin-Fixed Paraffin-Embedded.
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Japan) fitted with an emitter tip (FortisTip, OmniSeparo-
TJ, Hyogo, Japan). Peptide-mixture samples processed
from FFPE tissues were loaded onto the trap cartridge and
washed with mobile phase A (98% H2O with 2% aceto-
nitrile and 0.1% formic acid) for concentration and
desalting. Subsequently, the samples were eluted over
70 min from the analytical column via the trap cartridge
using a linear gradient of 5–40% mobile phase B (10%H2O with 90% acetonitrile and 0.1% formic acid) at a
flow-rate of 1 μL/min. General MS conditions were as
follows: electrospray voltage, 3.0 kV, no sheath and auxil-
iary gas flow; ion transfer tube temperature, 200C; colli-
sion energy, 35%; ion selection threshold, 1000 counts for
MS/MS. MS/MS was performed on the top 3 ions in each
MS scan using the dynamic exclusion principle, i.e. tem-
porary (180 s) placement of a mass on an exclusion list
after its MS/MS spectrum has been acquired.
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All MS/MS spectral data were searched against Homo
sapiens entries in the Swiss-Prot database (Release 57.13,
20,349 entries) using MASCOT software (version 2.1.1,
Matrix Science, UK). The peptide mass tolerance was
20 ppm, fragment mass tolerance 0.8 Da, and trypsin
specificity was applied with a maximum of 2 missed
cleavages. For variable peptide modifications, methio-
nine oxidation, and N-formylation, including formyl (K),
formyl (R), and formyl (N-terminus), were taken into ac-
count. To estimate the false positive rate for protein
identification, a decoy database was created by reversing
the protein sequences in the original database. Based on
search results for the decoy database, the estimated false
positive rate of peptide matches was 4.0% under P < 0.05
for protein score threshold conditions. Results were
obtained from triplicate LC-MS/MS runs for each
sample.
Spectral counting analysis of identified proteins
To compare protein expression across all tissue samples
from the results of shotgun analysis, I used the label-free
spectral counting method [18]. The number of peptide
spectra with high confidence (Mascot ion score, P <
0.05) served as the spectral count value. All proteins
with at least one peptide spectrum in a single LC-MS
/MS analysis were considered for protein quantification
using spectral counting. The averaged values based on
triplicate analyses were estimated as the spectral count
values of each protein for individual tissue samples, tak-
ing into consideration statistical significance.
Fold changes in expressed proteins on a base-2 loga-
rithmic scale were calculated using the protein ratio from
spectral counting (Rsc) [22]. Rsc > 1 or < −1 corresponds
to fold changes > 2 or < 0.5. Differences in relative
abundances of identified proteins were also assessed by
spectral index (SpI), allowing group comparison [23]. SpI
values ranged from −1 to +1, and those close to 0
indicated near-equal relative peptide abundance in the
2 groups. Candidate proteins of the 2 groups chosen
based on Rsc > 1 or < −1 and SpI > 0.75 or < -0.75, showed
statistical significance at P < 0.05 by non-parametric
G-test [24].
Immunohistochemistry
Immunohistochemistry was performed using FFPE tissue
sections stained with the horseradish peroxidase EnVi-
sion + System (DAKO, CA, USA). Antigen retrieval was
performed by heating the sections in 10 mmol/L citrate
buffer (pH 6.0) for 5 minutes. Mouse monoclonal nm23/
nucleoside diphosphate kinase-A (Nm23/NDPK-A) anti-
body, clone37.6 (Abcam, MA, USA), was used as the
primary antibody at a 1:100 dilution. A breast cancer tis-
sue section served as the positive control [25]. Fornegative controls, mouse IgG2a isotype control (R&D
Systems, MN, USA) was used as the primary antibody.
The sections were lightly counterstained with hematoxylin.
After completely reviewing all slides of immunostained
sections for each carcinoma, three of the authors (T.T., T.
O. and T.S.) independently and blindly classified carcinoma
cases into 2 groups: those in which the percentage of car-
cinoma cells positive for Nm23/NDPK-A exceeded 10%
were the positive group, while the negative group
comprised those with fewer than 10% positive cells, as in
previous studies [26,27].Statistical analysis
The χ2-test was used to compare categorical variables. In
univariate analysis, survival rates were calculated by the
Kaplan-Meier method and compared using the log-rank
test. In multivariate analysis, independent prognostic
factors were determined by the Cox proportional
hazards model. P < 0.05 was considered statistically sig-
nificant. JMP software version 9.0 was used for all ana-
lyses. Analyses were performed using only available data;
missing information was assumed to be non-informative.Results
The present study aimed to investigate molecular
profiles of proteins relevant to pancreatic cancer and to
confirm these proteins to be potential prognostic
biomarkers. The workflow is illustrated in Figure 2.Patient characteristics
First, we performed shotgun proteomic analysis using
FFPE tissues from 8 invasive pancreatic ductal carcin-
omas. The better and poor prognostic groups each
provided 4 independent primary tumor tissues. The 2
groups did not differ in age, gender, tumor location,
pathological staging, lymph node metastasis, tumor dif-
ferentiation, postoperative CA19-9, or adjuvant chemo-
therapy (Table 1).Protein identification and semi-quantitative comparison
In shotgun proteomic analysis, 845 proteins in the better
prognostic group, 924 in the poor prognostic group and
1099 proteins in total were identified (Additional file 1:
Table S1). The identified proteins were semi-quantitatively
compared using spectral counting analysis. We identified
that ADP-ribosylation factor 4 (ARF4), Collagen alpha-3
(VI) chain (CO6A3), DNA-binding protein A (DBPA),
Malate dehydrogenase, cytoplasmic (MDHC), Nucleoside
diphosphate kinase A (NDKA) and Probable transcription
factor PML (PML) were differentially expressed in the 2
groups, including 4 and 2 over-expressed proteins in the
poor and better prognostic groups, respectively (Table 2).
Figure 2 Strategy for shotgun proteomic analysis and
immunohistochemical confirmation. a Liquid chromatography-
tandem mass spectrometry.




group (n = 4)
Better
prognostic






Mean ± SDa 21.0 ± 4.80 58.1 ± 13.0 0.0067b
Age Mean ± SD 66.75 ± 10.66 63.25 ± 12.95 0.6909c
Gender Male 3(75) 3(75)
Female 1(25) 1(25)
Location Head 4(100) 4(100)
T T3 4(100) 4(100)
N N1 4(100) 4(100)
M M0 4(100) 4(100)
UICC stage IIB 4(100) 4(100)
JPS stage 3 4(100) 4(100)
Differentiation Moderate 4(100) 4(100)
Residuum R0 4(100) 4(100)
Postoperative
CA19-9





b The log-rank test was used.
c The t-test was used.
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To confirm expressions of the 6 candidate proteins in tis-
sue sections, we immunohistochemically analyzed the 8
cases with shotgun proteomic data. Among the 6 candi-
date proteins, we focused on NDKA (also called Nm23/
NDPK-A), because the immunohistochemical results
were most compatible with those of spectral counting
analysis. Nm23/NDPK-A has previously been described
as being associated with prognosis in non-pancreatic
cancers. Nm23/NDPK-A was over-expressed in the poor
prognostic group on semi-quantitative comparison. Theimmunostaining results for Nm23/NDPK-A are shown in
Figure 3. As with semi-quantitative analysis, 3 of 4 cases
were negative in the better prognostic group, while all 4
cases in the poor prognostic group were positive for
Nm23/NDPK-A, which was detected in the carcinoma
cell cytoplasm.
Relationships between Nm23/NDPK-A expression and
clinicopathological features in 96 invasive pancreatic
ductal carcinoma patients
To confirm the association between Nm23/NDPK-A and
the prognosis of invasive pancreatic ductal carcinoma,
we immunohistochemically analyzed a 96-case cohort
(62 men, 34 women; mean age, 64 years). Baseline
characteristics are presented in Table 3. Median survival
of patients in this cohort was 19.1 months and 20.4%
were alive at 5 years. Nm23/NDPK-A was expressed in
the carcinoma cell cytoplasm in 73 of the 96 (76%)
tumor specimens. Nm23/NDPK-A expression status was
compared across survival-associated clinical parameters
(Table 3). Nm23/NDPK-A staining patterns did not
differ by age, gender, tumor location, histological dif-
ferentiation, pathological stage, lymph node metas-
tasis, National Comprehensive Cancer Network (NCCN)
resectability status, pre- and postoperative CA19-9
levels, or adjuvant chemotherapy. It was suggested
that Nm23/NDPK-A was a potentially independent
Table 2 Proteins identified differentially expressed between better and poor prognostic groups
Accession
number














P15531 NDKA_HUMAN Nucleoside diphosphate kinase A 1 6 1.74 0.82 3.88 0.049
P16989 DBPA_HUMAN DNA-binding protein A 2 10 1.85 0.79 5.89 0.015
P18085 ARF4_HUMAN ADP-ribosylation factor 4 5 25 2.13 0.79 15.1 < 0.01
P12111 CO6A3_HUMAN Collagen alpha-3(VI) chain 6 31 2.21 0.76 19.2 < 0.01
P29590 PML_HUMAN Probable transcription factor PML 10 1 −2.27 −0.89 7.85 <0.01
P40925 MDHC_HUMAN Malate dehydrogenase, cytoplasmic 7 0 −2.67 −1 8.81 <0.01
a protein ratio from spectral counting.
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investigated the correlation between the expression of
Nm23/NDPK-A and prognosis.
The χ2-test was used to compare categorical variables.
None of the categories was significantly associated with
Nm23/NDPK-A status.
Survival and the expression of Nm23/NDPK-A
Kaplan-Meier analysis revealed patients with carcinoma
cells expressing Nm23/NDPK-A to have significantly
worse overall survival (OS) and disease free survival
(DFS) than those without Nm23/NDPK-A (Figure 4, OS;
P = 0.0103, DFS; P = 0.0186). In univariate analysis,
lymph node metastasis (P = 0.0039), NCCN criteria (P =
0.0339), postoperative CA19-9 level (P = 0.0082), and
Nm23/NDPK-A expression (P = 0.0103) were signifi-
cantly associated with worse OS (Table 4). With theFigure 3 Immunohistochemistry for Nm23/NDPK-A in invasive pancre
NDPK-A immunoreactivity was detected in the cytoplasm of carcinoma cel
cells. Scale bar = 100 μm, original magnification, ×200.multivariate Cox regression model, lymph node metasta-
sis (Hazard Ratio [HR] 2.20, 95% Confidence Interval
[CI] 1.33-3.80, P = 0.0020), postoperative CA19-9 level
(HR 1.92, 95% CI 1.21-3.04, P = 0.0062), and Nm23/
NDPK-A expression (HR 1.97, 95% CI 1.16-3.56, P =
0.0110) remained independent factors predicting poor
survival (Table 4).
Univariate analysis was performed using the log-rank
test. Multivariate analysis was performed using the Cox
proportional hazard model for variables that were sig-
nificant on univariate analysis.
Discussion
Recently, efforts have been made to identify novel bio-
marker proteins by gene microarray and proteomics
methods. Pancreatic cancer is aggressive and has an
extremely poor prognosis due to delayed diagnosis,atic ductal carcinoma. A), B) hematoxylin-eosin staining, C) Nm23/
ls. D) No Nm23/NDPK-A immunoreactivity was detected in carcinoma















Age < 65 45 (47%) 32 (44%) 13 (57%) 0.2877
≥ 65 51 (53%) 41 (56%) 10 (43%)
Gender Male 62 (65%) 45 (62%) 17 (74%) 0.2833
Female 34 (35%) 28 (38%) 6 (26%)
Location Head 73 (76%) 56 (77%) 17 (74%) 0.7839
Body-Tail 23 (24%) 17 (23%) 6 (26%)
Histological
differentiationa
Well 8 (8%) 6 (8%) 2 (9%) 0.9838
Moderate +
Poor
77 (80%) 58 (80%) 19 (82%)
Tumor stage T1 + T2 10 (10%) 7 (10%) 3 (13%) 0.6363
T3 + T4 86 (90%) 66 (90%) 20 (87%)
Nodal stage N0 33 (34%) 25 (34%) 8 (35%) 0.9624
N1 63 (66%) 48 (66%) 15 (65%)
NCCNb criteria Resectable 50 (52%) 38 (52%) 12 (52%) 0.9920
Borderline
rsectable
46 (48%) 35 (48%) 11 (48%)
Preoperative
CA19-9
< 37 U/mL 25 (26%) 17 (23%) 8 (35%) 0.2733
≥ 37 U/mL 71 (74%) 56 (77%) 15 (65%)
Postoperative
CA19-9
< 37 U/mL 57 (59%) 41 (56%) 16 (70%) 0.2538
≥ 37 U/mL 39 (41%) 32 (44%) 7 (30%)
Adjuvant
chemotherapy
Gemcitabine 58 (60%) 42 (58%) 16 (70%) 0.3035
Othersc 38 (40%) 31 (42%) 7 (30%)
a Other histological classifications including papillary, mucinous,
adenosquamous and anaplastic carcinoma in 11 cases.
b National Comprehensive Cancer Network.
c Others include 5FU and surgery alone.
Figure 4 Survival analysis for Nm23/NDPK-A immunoreactivity
by the Kaplan-Meier method. A) Nm23/NDPK-A positivity was
significantly associated with poor overall survival (log-rank test, P =
0.0103). B) Nm23/NDPK-A positivity was significantly associated with
poor disease free survival (log-rank test, P = 0.0186). The day of
recurrence was unclear in 11 cases.
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Thus, it is very important to find new diagnostic, prognos-
tic and therapeutic biomarkers [16]. We explored novel
independent prognostic biomarkers of pancreatic cancer
by shotgun proteomics using LC-MS/MS, with cli-
nically-documented micro-dissected FFPE tissues, spectral
counting for semi-quantification and immunohistochemical
confirmation.
FFPE, a routine process providing easily-stored ar-
chived tissues, is well-defined pathologically. Extensive
FFPE tissue archives have been collected and stored at
room temperature for decades in hospitals worldwide.
FFPE tissue contains associated clinical and experimen-
tal information representing an extremely valuable, un-
tapped reservoir of protein biomarkers [18,20]. For
decades, however, FFPE tissue has been used only for
light microscopic diagnosis and staging of tumors [28].A methodological limitation is that, due to various
combinations of intra- and inter-molecular covalent
cross-linking between proteins by formaldehyde, proteins
are preserved but rendered insoluble [28-30]. Recent
developments in extraction methodologies have finally
made analysis of FFPE tissue by MS possible, providing
access to this vast and clinically important sample set for
biomarker discovery [18,20,31-33]. By spectral counting
for semi-quantification, we identified 6 proteins differen-
tially expressed in the 2 groups, including 4 and 2 over-
expressed proteins in the poor and better prognostic
groups, respectively. Though we confirmed all 6 candi-
date proteins, we focused on Nm23/NDPK-A because its
immunohistochemical results were most compatible with
those of spectral counting analysis. Nm23/NDPK-A has
previously been described as being associated with prog-
nosis in non-pancreatic cancers.
Table 4 Univariate and Multivariate analyses of clinicopathological factors influencing overall survival




HRa 95% CIb P value by Cox
proportional hazards
Gender Male 62 0.1288
Female 34
Age < 65 45 0.8967
≥ 65 51
Location Head 73 0.8589
Body-Tail 23
Histological differentiation Well 8 0.2069
Moderate + Poor 77
Tumor stage T1 + T2 10 0.1996
T3 + T4 86
Nodal stage N0 63 0.0039 2.20 1.33-3.80 0.0020
N1 33
NCCN criteria Resectable 50 0.0339 1.40 0.90-2.21 0.1419
Borderline resectable 46
Preoperative CA19-9 < 37 U/mL 25 0.3444
≥ 37 U/mL 71
Postoperative CA19-9 < 37 U/mL 57 0.0082 1.92 1.21-3.04 0.0062
≥ 37 U/mL 39
Adjuvant chemotherapy Gemcitabine 58 0.4201
Others 38
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tive metastasis suppressors based on reduced expression
in certain highly metastatic cell lines and tumors [34,35].
In humans, 10 genes belong to the NM23 gene family
(also known as NME genes). The two most abundantly
expressed are NM23-H1 and NM23-H2 encoding the A
and B subunits, respectively, of NDPK [36]. Nm23/
NDPK-A has several biochemical functions [37]: 1) nu-
cleoside diphosphate kinase, 2) phosphotransferase and
histidine protein kinase, 3) 3’-5’-exonuclease, and 4)
regulation of GTP-binding proteins. Inverse correlations
between NM23-H1 expression and high tumor meta-
static potential in several tumor types, e.g. hepatocellular
carcinoma, melanomas, breast cancer, ovarian cancer
and gastric cancer, have been demonstrated [38-41]
In other human carcinomas, such as colon cancer, pan-
creatic ductal carcinoma, neuroblastoma and non-
Hodgkin’s lymphoma, high mRNA and protein levels of
NM23-H1 have been detected in aggressive tumors
[25,42-47]. Andolfo et al reported that NM23-H1
functioned as an inhibitor of tumor invasion in vitro, but
had the opposite function in vivo [27]. Although the
mechanisms underlying these differences are presentlyunknown, the action of Nm23/NDPK-A might be altered
or regulated in different ways in various organs, under
the influence of other genes and proteins.
Only a few studies have examined Nm23/NDPK-A
expression in pancreatic cancer. Nakamori et al
reported strong immunoreactivity for Nm23/NDPK-A
and -B to be associated with lymph node metastasis
and poor prognosis in 47 pancreatic cancer cases
[25,44]. We immunohistochemically analyzed Nm23/
NDPK-A in 96 cases, a larger sample size than that of
Nakamori et al. Our findings also indicated higher
Nm23/NDPK-A expression levels to be associated with
poor prognosis, but there was no significant correl-
ation with lymph node metastasis. Furthermore, in our
study, Nm23/NDPK-A expression was an independent
prognostic factor for OS on multivariate analysis.
Ohshio et al found no significant correlation between
Nm23/NDPK-A expression and prognosis of resected
cases [42]. This discrepancy in results between our
study and that of Ohshio et al. might reflect
differences in sample case backgrounds. Nakamori et
al and our group examined only resected pancreatic
cancer samples whereas Ohshio et al. investigated
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metastases.
Although further study is needed to determine the
precise role of Nm23/NDPK-A in malignant behavior of
cells, Nm23/NDPK-A expression is potentially useful
for assessing prognosis or selecting treatments in pan-
creatic cancer patients. Positivity for Nm23/NDPK-A in
resected specimens might serve as an index providing
information useful to physicians for the administration
of adjuvant therapy and intensive follow-up of cancer
patients likely to suffer a recurrence. By combining the
expression of Nm23/NDPK-A, lymph node matastasis
and postoperative CA19-9 level that were independent
prognostic factors in this study, it might be possible
to know the prognosis and make treatment more accur-
ately. Herein, Nm23/NDPK-A expression was confirmed
immunohistochemically, though Okabe-Kado et al.
reported that the serum Nm23/NDPK-A level may con-
tribute to predicting prognosis of neuroblastoma
patients [48]. It would be interesting to examine whether
serum Nm23/NDPK-A levels are associated with poor
prognosis of postoperative pancreatic cancer patients.
Identification of Nm23/NDPK-A by immunocytochem-
istry using endoscopic ultrasound-guided fine needle as-
piration or brushing cytology specimens might be also
anticipated to be useful for diagnosis and selecting opti-
mal treatments for preoperative patients. Moreover, if
the precise role of Nm23/NDPK-A in malignant behav-
ior of cells is elucidated, Nm23/NDPK-A might be thera-
peutic target.
Conclusions
We performed a proteomic analysis to identify novel prog-
nostic biomarkers for postoperative pancreatic cancer using
FFPE tissues. We semi-quantitatively compared expressed
proteins between poor and better prognostic groups. The
results were immunohistochemically confirmed. A high
level of Nm23/NDPK-A expression correlated with poor
OS and DFS. Measurement of Nm23/NDPK-A expression
is potentially useful for obtaining prognostic and treatment
information for pancreatic cancer patients. MS-based
proteomic analysis with FFPE tissue offers new opportun-
ities to identify biomarkers and therapeutic targets using
archival samples with their corresponding pathological and
clinical records.
Additional file
Additional file 1: Table S1. The list of all proteins identified in shotgun
proteomic analysis.
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